Globus Medical (NYSE:GMED) Q3 2025 Earnings Call November 06, 2025 04:30 PM ET Speaker1Welcome to Globus Medical's third quarter 2025 earnings call. At this time, all lines will be on mute, and a Q&A session will be held after the prepared remarks. To ask a question during the session, you will need to press Star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press Star 11 again. Please be advised that today's conference is being ...

Financial Data and Key Metrics Changes - Globus Medical reported Q2 sales of $745 million, with non-GAAP EPS of $0.86, reflecting growth of 18.4% and 14.1% respectively compared to the prior year quarter [14][42] - Free cash flow was $31.3 million, growing 18% despite the impact of the Nevro acquisition and higher CapEx spending [14][36] - Adjusted EBITDA margins for the base Globus business were 32.3%, growing 210 basis points over the prior year quarter [36][52] Business Line Data and Key Metrics Changes - The base business generated $651 million in revenue during Q2, growing 3.3% as reported and 4.9% day adjusted [14][46] - Nevro contributed $95 million in revenue during the quarter, with operational challenges largely subsided [15][47] - The U.S. Spine business grew 5.7% as reported or 7.4% on a day adjusted basis, driven by key procedures and consistent growth [16][17] Market Data and Key Metrics Changes - U.S. revenue during Q2 was $600.8 million, growing 20.3% as reported [49] - International revenue was $144.6 million, growing 11% as reported and 7.5% on a constant currency basis [51] - The EMEA region saw growth led by the UK, Spain, Germany, Ireland, and Italy, while the APAC region focused on Japan and Australia [21][23] Company Strategy and Development Direction - The company aims to become the preeminent musculoskeletal technology company, focusing on improving clinical outcomes and addressing unmet clinical needs [10][11] - There is a strong emphasis on integrating merged and acquired entities, accelerating product development, and maintaining financial discipline [12][13] - The strategy includes expanding the product portfolio and enhancing the sales force through competitive rep conversions [12][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position in the market and the potential for organic growth, particularly in the U.S. Spine business [12][34] - The integration of Nevro is expected to drive top-line growth while rightsizing profitability [59] - The leadership transition is viewed as an inflection point for growth, with confidence in the new CEO and CFO [88][90] Other Important Information - The company remains debt-free while generating strong free cash flow and investing in business growth [36][57] - The acquisition of Nevro was seen as a strategic opportunity, enhancing the product portfolio and addressing a broader continuum of care [30][45] - The company has launched 21 new products since the beginning of 2024, with a focus on innovation and filling gaps in the product portfolio [32][33] Q&A Session Summary Question: Progress with Nevro - Management expressed cautious optimism about the integration of Nevro, highlighting energized sales force and early benefits from cost containment activities [66][70] Question: Enabling Technology and Robots - Enabling Technologies saw a bounce back in Q2, with the pipeline remaining active and no significant loss of deals to competition [71][73] Question: Investor Communication Strategy - The company plans to enhance investor outreach and will hold an Investor Day in the future [78][79] Question: Augmented Reality Headset Launch - The launch plan for the augmented reality headset is underway, with a focus on integrating it into the Excelsius ecosystem [81][83] Question: Leadership Transition - Management reassured investors about the continuity in leadership and the depth of the leadership bench, emphasizing stability and strategic focus [87][88] Question: Nevro's Growth Strategy - The strategy for Nevro includes stability in approach, honing product development, and consistent commercial strategy to ensure long-term growth [91][93]